This inventor holds 2 USPTO granted patents and 3 published patent applications, plus 1 CIPO patent and 1 EPO patent. Top assignee: Lek Pharmaceuticals D.d.. Active years: 2011-2016.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2011-2016
Title: The Innovative Mind of Matjaz Kracun
Introduction
Matjaz Kracun is a notable inventor based in Ljubljana, Slovenia. With a total of two patents to his name, he has made significant contributions to the field of pharmaceuticals, particularly concerning atorvastatin calcium.
Latest Patents
Matjaz's latest patents include innovations focusing on the oxidative degradation products of atorvastatin calcium. The first patent details the oxidative degradation products and the process for their preparation, ensuring that atorvastatin calcium is substantially free from harmful oxidative degradation products. This invention also encompasses pharmaceutical compositions that utilize such atorvastatin calcium, thereby enhancing the efficacy and safety of the medication.
Career Highlights
Matjaz Kracun is currently employed at Lek Pharmaceuticals d.d., a prominent company in the pharmaceutical industry. His work has been pivotal in developing safer and more effective pharmaceutical formulations that can improve patient outcomes. With a rich background in pharmaceutical research, he continues to drive innovations in his field.
Collaborations
Throughout his career, Matjaz has worked alongside talented colleagues, including Rok Grahek and Darko Kocjan. Their collaborative efforts have further advanced their projects, culminating in meaningful innovations that benefit healthcare.
Conclusion
In summary, Matjaz Kracun stands out as an influential inventor whose work in the pharmaceutical sector is making a difference. His recent patents not only showcase his dedication to innovation but also underline the importance of research in creating effective medical solutions. His ongoing contributions at Lek Pharmaceuticals d.d. promise to continue shaping the future of pharmaceuticals.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile